Improving drug discovery with contextual assays and cellular systems analysis

Area of Science:

• Biotechnology
• Pharmacology
• Genomics

Background:

• Drug discovery success rates remain low despite advances in human genome knowledge.
• Early-stage drug development, particularly target transition to preclinical stages, has a success rate below 3%.
• Poor understanding of therapeutic mechanisms and compound selectivity contribute to high failure rates.

Purpose of the Study:

• To address the low success rate in therapeutic discovery.
• To develop a strategy for assessing drug targets in their native biological context.
• To enable broad assessment of chemical space for small molecule and genetic therapeutics while retaining high throughput.

Main Methods:

• An integrated system combining high-content cellular analysis with system-wide pathway interrogation.
• Application of the platform for novel therapeutic target and drug candidate identification.
• Generation of detailed mechanistic and selectivity information at early development stages.

Main Results:

• The described platform facilitates early-stage assessment of therapeutic targets and drug candidates.
• The system provides mechanistic and selectivity insights crucial for development.
• This approach aims to improve the success rate of new therapeutic discovery.

Conclusions:

• The integrated system offers a novel approach to overcome challenges in early-stage drug discovery.
• High-content analysis and pathway interrogation can provide essential data for target and candidate selection.
• This strategy supports the development of more effective and selective therapeutics.